Lower GI 2017

ACCORD 12/0405

CAO/ARO/ AIO-04

NSABP R-04

STAR-01

PETACC-6

Endpoint

PCR

16% both arms

14% vs 19%

12.8% vs 16.5% (p=0.038)

19% vs 21%

11.5% vs 13%

CRM

4% vs 7%

8% vs 13%

5% vs 6% No data

2% vs 2%

Oxaliplatin Phase III trials: Control arm in red